225 related articles for article (PubMed ID: 18468741)
1. Active immunisation with RAMA does not provide protective immunity against Plasmodium yoelii challenge despite its association with protective responses in endemic populations.
Kats LM; Wang L; Murhandarwati EE; Mitri K; Black CG; Coppel RL
Vaccine; 2008 Jun; 26(26):3261-7. PubMed ID: 18468741
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of Plasmodium yoelii merozoite surface protein 4/5 produced in transgenic plants.
Wang L; Webster DE; Campbell AE; Dry IB; Wesselingh SL; Coppel RL
Int J Parasitol; 2008 Jan; 38(1):103-10. PubMed ID: 17681344
[TBL] [Abstract][Full Text] [Related]
3. Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge.
Wang L; Goschnick MW; Coppel RL
Infect Immun; 2004 Oct; 72(10):6172-5. PubMed ID: 15385527
[TBL] [Abstract][Full Text] [Related]
4. AAV vectors encoding malarial antigens stimulate antigen-specific immunity but do not protect from parasite infection.
Logan GJ; Wang L; Zheng M; Cunningham SC; Coppel RL; Alexander IE
Vaccine; 2007 Jan; 25(6):1014-22. PubMed ID: 17081661
[TBL] [Abstract][Full Text] [Related]
5. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells.
Hirunpetcharat C; Tian JH; Kaslow DC; van Rooijen N; Kumar S; Berzofsky JA; Miller LH; Good MF
J Immunol; 1997 Oct; 159(7):3400-11. PubMed ID: 9317139
[TBL] [Abstract][Full Text] [Related]
6. Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine.
Wang R; Charoenvit Y; Corradin G; Porrozzi R; Hunter RL; Glenn G; Alving CR; Church P; Hoffman SL
J Immunol; 1995 Mar; 154(6):2784-93. PubMed ID: 7876549
[TBL] [Abstract][Full Text] [Related]
7. Protective human immunity as a vaccine discovery tool for falciparum malaria.
Nixon CP; Friedman JF; Knopf PM; Duffy PE; Kurtis JD
Transfusion; 2005 Aug; 45(2 Suppl):81S-87S. PubMed ID: 16086793
[TBL] [Abstract][Full Text] [Related]
8. A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria.
Rainczuk A; Scorza T; Spithill TW; Smooker PM
Infect Immun; 2004 Oct; 72(10):5565-73. PubMed ID: 15385453
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
10. Plasmodium: mammalian codon optimization of malaria plasmid DNA vaccines enhances antibody responses but not T cell responses nor protective immunity.
Dobaño C; Sedegah M; Rogers WO; Kumar S; Zheng H; Hoffman SL; Doolan DL
Exp Parasitol; 2009 Jun; 122(2):112-23. PubMed ID: 19249301
[TBL] [Abstract][Full Text] [Related]
11. Fc receptors are not required for antibody-mediated protection against lethal malaria challenge in a mouse model.
Rotman HL; Daly TM; Clynes R; Long CA
J Immunol; 1998 Aug; 161(4):1908-12. PubMed ID: 9712060
[TBL] [Abstract][Full Text] [Related]
12. Plasmodium yoelii: experimental evidences for the conserved epitopes between mouse and human malaria parasite, Plasmodium falciparum.
Xu L; Pei X; Berzins K; Chaudhuri A
Exp Parasitol; 2007 Jul; 116(3):214-24. PubMed ID: 17336297
[TBL] [Abstract][Full Text] [Related]
13. A protective monoclonal antibody recognizes an epitope in the carboxyl-terminal cysteine-rich domain in the precursor of the major merozoite surface antigen of the rodent malarial parasite, Plasmodium yoelii.
Burns JM; Majarian WR; Young JF; Daly TM; Long CA
J Immunol; 1989 Oct; 143(8):2670-6. PubMed ID: 2477452
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic potential of liposomized integral membrane protein of Plasmodium yoelii nigeriensis against blood stage infection in BALB/c mice.
Sharma SK; Gupta C; Dwivedi V; Misra-Bhattacharya S; Mohammad O
Vaccine; 2007 Mar; 25(11):2103-11. PubMed ID: 17241709
[TBL] [Abstract][Full Text] [Related]
15. Identification of minimal CD8+ and CD4+ T cell epitopes in the Plasmodium yoelii hepatocyte erythrocyte protein 17kDa.
Dobaño C; Doolan DL
Mol Immunol; 2007 Apr; 44(11):3037-48. PubMed ID: 17303242
[TBL] [Abstract][Full Text] [Related]
16. Absolute requirement for an active immune response involving B cells and Th cells in immunity to Plasmodium yoelii passively acquired with antibodies to the 19-kDa carboxyl-terminal fragment of merozoite surface protein-1.
Hirunpetcharat C; Vukovic P; Liu XQ; Kaslow DC; Miller LH; Good MF
J Immunol; 1999 Jun; 162(12):7309-14. PubMed ID: 10358180
[TBL] [Abstract][Full Text] [Related]
17. Influence of glycosylphosphatidylinositol anchorage on the efficacy of DNA vaccines encoding Plasmodium yoelii merozoite surface protein 4/5.
Wang L; Kedzierski L; Schofield L; Coppel RL
Vaccine; 2005 Jul; 23(32):4120-7. PubMed ID: 15964480
[TBL] [Abstract][Full Text] [Related]
18. DNA immunization by Plasmodium falciparum liver-stage antigen 3 induces protection against Plasmodium yoelii sporozoite challenge.
Sauzet JP; Perlaza BL; Brahimi K; Daubersies P; Druilhe P
Infect Immun; 2001 Feb; 69(2):1202-6. PubMed ID: 11160023
[TBL] [Abstract][Full Text] [Related]
19. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C
Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232
[TBL] [Abstract][Full Text] [Related]
20. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity.
Bongfen SE; Ntsama PM; Offner S; Smith T; Felger I; Tanner M; Alonso P; Nebie I; Romero JF; Silvie O; Torgler R; Corradin G
Vaccine; 2009 Jan; 27(2):328-35. PubMed ID: 18984024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
